Medtrum TouchCare Nano
Medtrum
What it is
A fully tubeless, phone-controlled hybrid closed loop: a low-profile patch pump and 14-day CGM run together off Medtrum's APGO algorithm, with an unusual 'log the meal, skip the carb count' auto-meal feature. CE-marked and available internationally, but the 160-person type 1 trial registry is stale and its recruitment status is unknown; no results are posted.
Editorial review: .
Most recent recorded citation date: 2026-03-18. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.See the linked studies and their populations →
- Benefit or performance
- Time in range: Manufacturer reports time-in-range rises early and holds, with further gains using auto-meal handling, but no peer-reviewed TIR figure is yet published. A 160-person randomized type 1 trial (NCT06363916) has passed its estimated completion date with a stale registry and no posted results.[4]
- Important harms and treatment burden
- Read the safety discussion and original sources. A missing summary does not establish safety.
- Approval and country access
- Country-specific approval and access are not summarized in this record.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Read the full discussion and original sources for follow-up duration and study limitations.
This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 60 × 20 + 65 × 20 + 70 × 10 + 80 × 20 + 55 × 5 + 55 × 5 + 50 × 5 + 65 × 5 + 45 × 10 = 6375; divide by total weight 100. Unrounded weighted result: 63.75.
Manufacturer reports time-in-range rises early and holds, with further gains using auto-meal handling, but no peer-reviewed TIR figure is yet published. A 160-person randomized type 1 trial (NCT06363916) has passed its estimated completion date with a stale registry and no posted results.[4]
Closed-loop algorithm modulates and suspends basal to defend against lows; safety/efficacy is the explicit endpoint of the registered pivotal trial, whose status is now unknown rather than recruiting.[4]
Hybrid closed loop automating basal 24/7 plus optional automatic meal-bolus delivery via Auto Meal Handling — logging a meal without carb counting is rare among AID systems.[3]
Fully tubeless patch pump plus on-body CGM controlled entirely from a smartphone, with no separate handheld controller (PDM) to carry.[1]
Average-glucose lowering is implied by the TIR claims but not yet quantified in a published type 1 study; pending the pivotal trial readout.[4]
Algorithmic basal modulation aims to smooth variability, but no published glucose-variability metrics are available yet for this system.[4]
Offers adjustable glucose targets the user can raise around activity; no published exercise-specific outcome data.[1]
User-set glucose targets and meal logging give meaningful control; the algorithm is proprietary (APGO) and not openly configurable.[1]
CE MDR Class III certified and rolling out across multiple international markets including Europe and Brazil; not US-cleared and availability is uneven.[2]
AID default: 50% glucose outcomes and low-glucose protection, 40% daily experience, 10% access and cost. Freedom includes tubing, wearability, water-use limits and controller requirements. These are editorial priorities; studies and device generations differ. Check each scorecard for its evidence and limits.
The full picture
The Medtrum TouchCare Nano is described as a fully tubeless hybrid closed loop: a small, low-profile patch pump and a 14-day continuous glucose sensor work together under Medtrum's proprietary APGO algorithm to automate basal insulin around the clock. There is no separate handheld controller — the pump and CGM are run entirely from a smartphone app, which keeps the on-body footprint minimal and the carry burden low. Its most distinctive feature is Auto Meal Handling: rather than counting carbohydrates and entering a number, the user logs the meal type and the system adjusts insulin from the glucose response.
The evidence is less mature than the marketing. Medtrum says a six-month, single-arm study in 95 people with type 1 diabetes found higher time in range among more frequent Auto Meal users while hypoglycaemia stayed low, but its ATTD report gives no numeric results and no peer-reviewed paper.5 The separate randomized 160-person trial, NCT06363916, could not be verified as recruiting: at the 8 August 2026 registry check, ClinicalTrials.gov showed status unknown because the record had not been updated since June 2024, its estimated November/December 2025 completion dates had passed, and no results were posted.4
The system holds manufacturer-reported EU CE MDR Class III certification and is expanding across international markets. It is not US-cleared, and as a hybrid rather than fully closed loop it still expects a meal-type announcement.
Sources
- [1]TouchCare Nano System · Manufacturer
- [2]Medtrum Advances Global Adoption of TouchCare Nano Hybrid Closed-Loop AID System · Science journalism
- [3]Medtrum touts meal logging tech for automated insulin delivery · Science journalism
- [4]Evaluation of Security and Efficacy of Medtrum Hybrid Closed Loop System (NCT06363916) · Trial registry · 2024-04-15 — Registry checked 8 August 2026: status UNKNOWN because it has not been verified since June 2024. Estimated primary completion November 2025 and study completion December 2025 have passed; no results are posted.
ClinicalTrials.gov. Evaluation of Security and Efficacy of Medtrum Hybrid Closed Loop System (NCT06363916). Registry checked 8 August 2026.
- [5]Medtrum advances toward fully closed-loop delivery with Auto Meal Handling at ATTD 2026 · Manufacturer · 2026-03-18 — Manufacturer report of a prospective, open-label, single-arm six-month study in 95 people with type 1 diabetes. It says more frequent Auto Meal use was associated with higher TIR and low hypoglycaemia, but provides no numeric outcome table or peer-reviewed paper.
Medtrum. Medtrum Advances Toward Fully Closed-Loop Insulin Delivery with Auto Meal Handling at ATTD 2026.